Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma

Figure 1 Serum α-fetoprotein levels in 107 patients with liver cirrhosis or hepatocellular carcinoma at late Barcelona Clinic Liver Cancer stages (A) and early Barcelona Clinic Liver Cancer stages (B). Each dot represents one patient. AFP: α-fetoprotein; HCC: Hepatocellular carcinoma; BCLC: Barcelona Clinic Liver Cancer.

Figure 2 Serum glypican-3 levels in 32 liver cirrhosis patients and in 37 hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer-stage A and B. A: Each dot represents one patient; B: Frequencies of α-fetoprotein (AFP) ≥ 400 μg/L and glypican-3 (GPC3) > 300 ng/L in hepatocellular carcinoma (HCC) patients at Barcelona Clinic Liver Cancer-stage A and B.

Figure 3 Immunohistochemistry staining of glypican-3 or α-fetoprotein in liver samples. Representative of the excised hepatocellular carcinoma samples stained with mouse anti-glypican-3 (GPC3) (A-C) or AFP (D, 4 ×); B (10 ×) and c (40 ×) are the amplified image of A (4 ×). The cells stained with yellow or brown particles were considered positive (arrows).

Figure 4 Immunohistochemistry staining of glypican-3 in needle biopsy. Three tissue sections (A-C, 10 ×) from patients with hepatic space occupying lesions with their serum α-fetoprotein < 400 μg/L. Glypican-3 was positively expressed in hepatocellular carcinoma (arrows).

Figure 5 Frequencies of serum α-fetoprotein ≥ 400 μg/L only (stripped bars), α-fetoprotein ≥ 400 μg/L and glypican-3 > 300 ng/L (filled bars) in 75 hepatocellular carcinoma patients at different Barcelona Clinic Liver Cancer stages. AFP: α-fetoprotein; GPC3: Glypican-3.